<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Syphilis BASHH 2024</h1><h3 class="text-lg font-semibold mt-6 mb-3"><strong>1  Headline 2024 changes</strong></h3><p>• Benzathine penicillin + lidocaine licensed and preferred.</p><p> • Macrolides removed (23S rRNA‑mediated resistance).</p><p> • Ceftriaxone accepted alternative when penicillin unsuitable.</p><p> • Expanded use of PCR; serology pathway updated after UK TPPA withdrawal.</p><p> • Management of serofast cases refined; LP indications narrowed; ≤14 d gap now tolerated between benzathine doses. fileciteturn4file9</p><p><strong>### 2  Organism &amp; epidemiology</strong></p><p> <em>Treponema pallidum</em> subsp. <em>pallidum</em>; human‑only reservoir, sexual or trans‑placental transmission. UK incidence rising since 2014, majority GBMSM but marked uptick in heterosexual and female cases.  </p><p><strong>### 3  Clinical staging (high‑yield features)</strong></p><table><tr><td><p><strong>Stage</strong></p></td><td><p><strong>Key clinical points</strong></p></td><td><p><strong>Still infectious?</strong></p></td><td><p><strong>First‑line therapy*</strong></p></td></tr><tr><td><p>Primary</p></td><td><p>Chancre (often painless; may be multiple). Dark‑ground/PCR positive before serology.</p></td><td><p>✔</p></td><td><p>BP† 2.4 MU IM ×1</p></td></tr><tr><td><p>Secondary</p></td><td><p>Rash incl. palms/soles, condylomata lata, alopecia; systemic (uveitis/meningitis). Beware prozone.</p></td><td><p>✔</p></td><td><p>BP 2.4 MU IM ×1</p></td></tr><tr><td><p>Early latent (&lt;2 y)</p></td><td><p>Asymptomatic but transmissible; 4‑fold RPR rise = active.</p></td><td><p>✔</p></td><td><p>BP 2.4 MU IM ×1</p></td></tr><tr><td><p>Late latent / tertiary</p></td><td><p>Gummata, aortitis, tabes dorsalis, paresis.</p></td><td><p>✖</p></td><td><p>BP 2.4 MU IM weekly ×3^</p></td></tr></table><p>*Alternatives see §5. </p><p>†BP = benzathine penicillin G.</p><p>^ gap can be up to 14 days</p><p><strong>### 4  Laboratory diagnosis</strong></p><p> <strong>Direct</strong> – Dark‑ground microscopy (operator‑dependent; avoid oral/rectal) and PCR (higher sensitivity, any site). fileciteturn4file13</p><p> <strong>Serology algorithm</strong></p><ol><li>EIA/CLIA (IgG ± IgM) screen.</li><li>Confirm with different treponemal test (TPHA/TPLA or 2nd EIA) + baseline quantitative RPR.</li><li>RPR ≥1:16 suggests activity; 4‑fold rise = new/relapse; dilute serum to avoid prozone. fileciteturn4file8</li></ol><p> <strong>Repeat testing rules</strong> – </p><ul><li>Ab screen pos, confirmatory neg &gt;2 weeks</li><li>lesion PCR‑/DGM‑ with high suspicion &gt; <strong>2 weeks</strong>; </li><li>high‑risk exposure &gt; repeat at <strong>3 months</strong>. fileciteturn4file12</li></ul><p> <strong>Serology pitfalls</strong> – </p><ul><li>False‑negatives in early infection (&lt;3 mo) or immunocompromise; </li><li>false‑positives in autoimmune disease, older age, people who inject drugs. fileciteturn4file12</li></ul><p> <strong>‘Serofast’</strong> – Low‑level persistent RPR after adequate therapy; no benefit from retreatment unless new evidence. fileciteturn4file18</p><p><strong>### 5  CSF / neurosyphilis pearls</strong></p><p> Lumbar puncture <strong>only if neuro/ocular/otological symptoms</strong> or <strong>serological treatment failure</strong>. fileciteturn4file19</p><p> <strong>CSF criteria supporting neurosyphilis</strong>: protein &gt; 0.45 g/L; WCC &gt; 5 cells/µL (HIV‑negative) or &gt; 20 cells/µL (untreated HIV); RPR + or TPHA &gt; 1:320. fileciteturn4file16</p><p> Refer early to ophthalmology / ENT / cardiology if relevant symptoms. fileciteturn4file15</p><p><strong>### 6  Antimicrobial therapy (memorise doses)</strong></p><table><tr><td><p><strong>Scenario</strong></p></td><td><p><strong>First‑line</strong></p></td><td><p><strong>Key alternatives</strong></p></td><td><p><strong>Notes</strong></p></td></tr><tr><td><p>Incubating / epidemiological</p></td><td><p>BP 2.4 MU IM ×1</p></td><td><p>Doxy 100 mg BD 14 d</p></td><td></td></tr><tr><td colspan="4"></td></tr><tr><td><p>Early syphilis</p></td><td><p>BP 2.4 MU IM ×1</p></td><td><p>Procaine Pen 600 000 U IM OD 10 d; Doxy 100 mg BD 14 d; Ceftriaxone 0.5–1 g IM/IV OD 10 d</p></td><td></td></tr><tr><td colspan="4"></td></tr><tr><td><p>Late latent / cardiovascular / gummata</p></td><td><p>BP 2.4 MU IM weekly ×3</p></td><td><p>Doxy 100 mg BD 28 d; Amox 2 g TDS + Probenecid QDS 28 d; Ceftriaxone 2 g OD 10–14 d</p></td><td></td></tr><tr><td colspan="4"></td></tr><tr><td><p><strong>Neurosyphilis</strong></p></td><td><p>Procaine Pen 1.8–2.4 MU IM OD + Probenecid 500 mg QDS 14 d <strong>or</strong> nBenzylpenicillin 1.8–2.4 g IV 6‑hourly 14 d</p></td><td><p>Ceftriaxone 2 g OD 10–14 d; Doxy 200 mg BD 28 d</p></td><td><p>Restart if &gt;24 h gap; never use benzathine here. </p></td></tr></table><p><strong>Penicillin allergy</strong> – Take detailed history; most labelled allergies are not true. Perform skin testing; if positive, desensitise <strong>in a setting with resus kit</strong>. Patients with soya/peanut allergy: avoid benzathine, use procaine penicillin or ceftriaxone. fileciteturn4file4turn4file6</p><p><strong>### 7  Jarisch–Herxheimer &amp; injection practicalities</strong></p><p> • Warn patients; observe 15 min after first injection; resus facilities on hand.</p><p> • Prednisolone 40–60 mg OD for 3 d starting 24 h pre‑therapy for neuro/cardiac/ocular disease.</p><p> • BP diluted with lidocaine improves tolerability; gaps ≤14 d between late‑syphilis BP doses acceptable. fileciteturn4file5</p><p><strong>### 8  Advice to patients</strong></p><p> • Abstain from sexual contact <strong>until lesions healed or 2 weeks after completing treatment</strong>. fileciteturn4file10</p><p> • Screen for other STIs, offer hepatitis B / HPV vaccines, discuss PrEP where appropriate.</p><p><strong>### 9  Follow‑up / test‑of‑cure</strong></p><p> • Minimum: RPR at 3, 6, 12 mo, then 6‑monthly until RPR negative or serofast. fileciteturn4file18</p><p> • ≥4‑fold RPR rise, symptoms or failure of expected fall → assess for re‑infection, treatment failure or neurosyphilis.</p><p> • Post‑neurosyphilis CSF re‑exam at 6 wk–6 mo if baseline abnormal. fileciteturn4file10</p><p><strong>### 10  Partner notification</strong></p><p> • Look‑back: 3 mo (primary) or 2 y (secondary/early latent); symptomatic partners receive epidemiological treatment or rescreen at 12 wk. fileciteturn4file6</p><p><strong>### 11  High‑yield exam pearls</strong></p><p> • TPPA withdrawn – labs use TPHA/TPLA or 2nd EIA for confirmation.</p><p> • Prozone phenomenon – always dilute serum if high suspicion.</p><p> • False‑positive treponemal tests common in autoimmune disease/IVDU; false‑negatives early or in immunocompromise. fileciteturn4file12</p><p> • CSF thresholds (protein &gt; 0.45 g/L; WCC &gt; 5 µL or &gt; 20 µL if HIV) and TPHA &gt; 1:320. fileciteturn4file16</p><p> • IM benzathine achieves treponemicidal serum for 2–4 wks (hence 14‑day gap rule). fileciteturn4file5</p><p> • Never use benzathine for neurosyphilis. fileciteturn4file16</p><p>These notes now include the repeat‑testing rules, serology caveats, numeric CSF criteria, expanded penicillin‑allergy guidance and patient abstinence advice requested.</p>
</div>